EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year operating income growth rate
Latest
-13.41%
↑ 91% vs avg
Percentile
P41
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-156.27%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -13.41% |
| Q3 2025 | 0.32% |
| Q2 2025 | -27.42% |
| Q1 2025 | -7.95% |
| Q4 2024 | -38.14% |
| Q3 2024 | 5.20% |
| Q2 2024 | -3.68% |
| Q1 2024 | -103.75% |
| Q4 2023 | -13.59% |
| Q3 2023 | 36.74% |
| Q2 2023 | -5.60% |
| Q1 2023 | 50.72% |
| Q4 2022 | -137.72% |
| Q3 2022 | 4.26% |
| Q2 2022 | -5.10% |
| Q1 2022 | -1.30% |
| Q4 2021 | -17.87% |
| Q3 2021 | -39.48% |
| Q2 2021 | -0.40% |
| Q1 2021 | 14.15% |
| Q4 2020 | -550.84% |
| Q3 2020 | 82.45% |
| Q2 2020 | 2.55% |
| Q1 2020 | -27.37% |
| Q4 2019 | 36.10% |
| Q3 2019 | -38.32% |
| Q2 2019 | 30.62% |
| Q1 2019 | -33.13% |
| Q4 2018 | 18.81% |
| Q3 2018 | -38.56% |
| Q2 2018 | -109.11% |
| Q1 2018 | 19.46% |
| Q4 2017 | 3.30% |
| Q3 2017 | 2.12% |
| Q2 2017 | -18.91% |
| Q1 2017 | -5389.36% |
| Q4 2016 | 98.69% |
| Q3 2016 | -11.31% |
| Q2 2016 | -26.69% |
| Q1 2016 | 2.71% |